Antibody Drug Conjugate Market Analysis - Forecast(2019 - 2024)

Report Code: HCR 0152 Report Format: PDF + Excel (Delivery in 48 Hrs)
Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Antibody drug conjugates is generally derived from the combination of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease. Antibody drug conjugates also known as anti-cancer drugs are promising and effective modalities for cancer therapies and is prepared on two major principles of antibody resistance and cell killing efficiency of highly potent active pharmaceutical ingredient (HPAPI). This report is focused on identifying market size for antibody drug conjugate globally. Increasing cancer patients and instances globally coupled with increasing R&D activities in the field of cancer treatment is one of the major drivers for the growth of the antibody drug conjugate market.

This report identifies the antibody drug conjugate market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to antibody drug conjugate market.

Antibody Drug Conjugate Market

Globally North America dominated market for antibody drug conjugate in 2015 due high investment in the field for cancer treatment, better medical infrastructure and better access to the population in the region. North America was followed by Europe and Asia-Pacific as the second and third largest markets respective in 2015. Demand for antibody drug conjugate in the Asia-Pacific region is estimated to be grow fastest during the period of study and is expected to be driven by developing medical infrastructure and various initiatives by government to provide better access to the people in the region. This report on global antibody drug conjugate also covers antibody drug conjugate market size by drug phase and available drug market and also based on various geographical regions.
  • On the basis of phase of drug availability anti-infective drug phase this report classified as follows : Clinical and Pre-Clinical
  • On the basis of availability of drugs global antibody drug conjugate market is segmented as follows: Approved Drugs (Adcetris, Kadcyla), Pipeline Drugs (T-DM1, CMC-544, CDX-011, SAR3419 and Others)
  • This report on global antibody drug conjugate is also classified on the basis of infection type covering all major types of infections as follows: HIV, Hepatitis B, Hepatitis C, Urinary Tract, Respiratory Candidiasis and Other Infections
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for antibody drug conjugate in each of the region.

This report identifies all the major companies operating in the global antibody drug conjugate market. Some of the major companies’ profiles in detail are as follows:
  • ImmunoGen
  • Immunomedics
  • Seattle Genetics     
  • Bayer HealthCare AG     
  • Pfizer Inc.
1. Antibody Drug Conjugate Market - Overview
1.1. Definitions and Scope
2. Antibody Drug Conjugate Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography
3. Antibody Drug Conjugate Market 
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis 
4. Antibody Drug Conjugate Market – Startup companies Scenario Premium
4.1. Top 10 startup company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Market Shares
4.1.4. Market Size and Application Analysis
4.1.5. Venture Capital and Funding Scenario
5. Antibody Drug Conjugate Market – Industry Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing business index
5.3. Case studies of successful ventures
5.4. Customer Analysis – Top 10 companies
6. Antibody Drug Conjugate Market Forces
6.1. Drivers
6.2. Constraints
6.3. Challenges
6.4. Porters five force model
6.4.1. Bargaining power of suppliers
6.4.2. Bargaining powers of customers
6.4.3. Threat of new entrants
6.4.4. Rivalry among existing players
6.4.5. Threat of substitutes 
7. Antibody Drug Conjugate Market - Strategic analysis
7.1. Value chain analysis
7.2. Opportunities analysis
7.3. Product life cycle
7.4. Suppliers and distributors Market Share
8. Antibody Drug Conjugate Market – By Phase (Market Size -$Million / $Billion)
8.1. Market Size and Market Share Analysis 
8.2. Application Revenue and Trend Research
8.3. Product Segment Analysis
8.3.1. Clinical
8.3.2. Pre-Clinical
9. Antibody Drug Conjugate Market – By Availability (Market Size -$Million / $Billion)
9.1. Approved Drugs
9.1.1. Adcetris
9.1.2. Kadcyla
9.2. Pipeline Drugs
9.2.1. T-DM1
9.2.2. CMC-544
9.2.3. CDX-011
9.2.4. SAR3419
9.2.5. Others
10. Antibody Drug Conjugate - By Geography (Market Size -$Million / $Billion)
10.1. Antibody Drug Conjugate Market - North America Segment Research
10.2. North America Market Research (Million / $Billion)
10.2.1. Segment type Size and Market Size Analysis 
10.2.2. Revenue and Trends
10.2.3. Application Revenue and Trends by type of Application
10.2.4. Company Revenue and Product Analysis
10.2.5. North America Product type and Application Market Size
10.2.5.1. U.S.
10.2.5.2. Canada 
10.2.5.3. Mexico 
10.2.5.4. Rest of North America
10.3. Antibody Drug Conjugate - South America Segment Research
10.4. South America Market Research (Market Size -$Million / $Billion)
10.4.1. Segment type Size and Market Size Analysis 
10.4.2. Revenue and Trends
10.4.3. Application Revenue and Trends by type of Application
10.4.4. Company Revenue and Product Analysis
10.4.5. South America Product type and Application Market Size
10.4.5.1. Brazil  
10.4.5.2. Venezuela
10.4.5.3. Argentina
10.4.5.4. Ecuador
10.4.5.5. Peru
10.4.5.6. Colombia 
10.4.5.7. Costa Rica
10.4.5.8. Rest of South America
10.5. Antibody Drug Conjugate - Europe Segment Research
10.6. Europe Market Research (Market Size -$Million / $Billion)
10.6.1. Segment type Size and Market Size Analysis 
10.6.2. Revenue and Trends
10.6.3. Application Revenue and Trends by type of Application
10.6.4. Company Revenue and Product Analysis
10.6.5. Europe Segment Product type and Application Market Size
10.6.5.1. U.K  
10.6.5.2. Germany 
10.6.5.3. Italy 
10.6.5.4. France
10.6.5.5. Netherlands
10.6.5.6. Belgium
10.6.5.7. Spain
10.6.5.8. Denmark
10.6.5.9. Rest of Europe
10.7. Antibody Drug Conjugate – APAC Segment Research
10.8. APAC Market Research (Market Size -$Million / $Billion)
10.8.1. Segment type Size and Market Size Analysis 
10.8.2. Revenue and Trends
10.8.3. Application Revenue and Trends by type of Application
10.8.4. Company Revenue and Product Analysis
10.8.5. APAC Segment – Product type and Application Market Size
10.8.5.1. China 
10.8.5.2. Australia
10.8.5.3. Japan 
10.8.5.4. South Korea
10.8.5.5. India
10.8.5.6. Taiwan
10.8.5.7. Malaysia
11. Antibody Drug Conjugate Market - Entropy
11.1. New product launches
11.2. M&A's, collaborations, JVs and partnerships
12. Antibody Drug Conjugate Market – Industry / Segment Competition landscape Premium
12.1. Market Share Analysis
12.1.1. Market Share by Country- Top companies
12.1.2. Market Share by Region- Top 10 companies
12.1.3. Market Share by type of Application – Top 10 companies
12.1.4. Market Share by type of Product / Product category- Top 10 companies
12.1.5. Market Share at global level- Top 10 companies
12.1.6. Best Practices for companies
13. Antibody Drug Conjugate Market – Key Company List by Country Premium
14. Antibody Drug Conjugate Market Company Analysis
14.1. Market Share, Company Revenue, Products, M&A, Developments
14.2. ImmunoGen
14.3. Immunomedics
14.4. Seattle Genetics   
14.5. Bayer HealthCare AG
14.6. Pfizer Inc
14.7. Roche/Genentech
14.8. Novartis
14.9. Heidelberg Pharma
14.10. Oxford BioTherapeutics
14.11. Agensys, Inc
14.12. Company 11
14.13. Company 12
14.14. Company 13 and more
"*Financials would be provided on a best efforts basis for private companies"
15. Antibody Drug Conjugate Market - Appendix
15.1. Abbreviations
15.2. Sources
16. Antibody Drug Conjugate Market - Methodology
16.1. Research Methodology
16.1.1. Company Expert Interviews
16.1.2. Industry Databases
16.1.3. Associations
16.1.4. Company News
16.1.5. Company Annual Reports
16.1.6. Application Trends
16.1.7. New Products and Product database
16.1.8. Company Transcripts
16.1.9. R&D Trends
16.1.10. Key Opinion Leaders Interviews
16.1.11. Supply and Demand Trends
List of Tables

Table 1: Antibody Drug Conjugate Market Overview 2019-2024
Table 2: Antibody Drug Conjugate Market Leader Analysis 2018-2019 (US$)
Table 3: Antibody Drug Conjugate Market Product Analysis 2018-2019 (US$)
Table 4: Antibody Drug Conjugate Market End User Analysis 2018-2019 (US$)
Table 5: Antibody Drug Conjugate Market Patent Analysis 2013-2018* (US$)
Table 6: Antibody Drug Conjugate Market Financial Analysis 2018-2019 (US$)
Table 7: Antibody Drug Conjugate Market Driver Analysis 2018-2019 (US$)
Table 8: Antibody Drug Conjugate Market Challenges Analysis 2018-2019 (US$)
Table 9: Antibody Drug Conjugate Market Constraint Analysis 2018-2019 (US$)
Table 10: Antibody Drug Conjugate Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Antibody Drug Conjugate Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Antibody Drug Conjugate Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Antibody Drug Conjugate Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Antibody Drug Conjugate Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Antibody Drug Conjugate Market Value Chain Analysis 2018-2019 (US$)
Table 16: Antibody Drug Conjugate Market Pricing Analysis 2019-2024 (US$)
Table 17: Antibody Drug Conjugate Market Opportunities Analysis 2019-2024 (US$)
Table 18: Antibody Drug Conjugate Market Product Life Cycle Analysis 2019-2024 (US$)
Table 19: Antibody Drug Conjugate Market Supplier Analysis 2018-2019 (US$)
Table 20: Antibody Drug Conjugate Market Distributor Analysis 2018-2019 (US$)
Table 21: Antibody Drug Conjugate Market Trend Analysis 2018-2019 (US$)
Table 22: Antibody Drug Conjugate Market Size 2018 (US$)
Table 23: Antibody Drug Conjugate Market Forecast Analysis 2019-2024 (US$)
Table 24: Antibody Drug Conjugate Market Sales Forecast Analysis 2019-2024 (Units)
Table 25: Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 26: Antibody Drug Conjugate Market By Phase, Revenue & Volume,By Clinical, 2019-2024 ($)
Table 27: Antibody Drug Conjugate Market By Phase, Revenue & Volume,By Pre-Clinical, 2019-2024 ($)
Table 28: Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 29: Antibody Drug Conjugate Market By Availability, Revenue & Volume,By Approved Drugs, 2019-2024 ($)
Table 30: Antibody Drug Conjugate Market By Availability, Revenue & Volume,By Pipeline Drugs, 2019-2024 ($)
Table 31: North America Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 32: North America Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 33: South america Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 34: South america Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 35: Europe Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 36: Europe Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 37: APAC Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 38: APAC Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 39: Middle East & Africa Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 40: Middle East & Africa Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 41: Russia Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 42: Russia Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 43: Israel Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 44: Israel Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 45: Top Companies 2018 (US$)Antibody Drug Conjugate Market, Revenue & Volume
Table 46: Product Launch 2018-2019Antibody Drug Conjugate Market, Revenue & Volume
Table 47: Mergers & Acquistions 2018-2019Antibody Drug Conjugate Market, Revenue & Volume


List of Figures

Figure 1: Overview of Antibody Drug Conjugate Market 2019-2024
Figure 2: Market Share Analysis for Antibody Drug Conjugate Market 2018 (US$)
Figure 3: Product Comparison in Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 4: End User Profile for Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Antibody Drug Conjugate Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Antibody Drug Conjugate Market 2018-2019
Figure 8: Ecosystem Analysis in Antibody Drug Conjugate Market 2018
Figure 9: Average Selling Price in Antibody Drug Conjugate Market 2019-2024
Figure 10: Top Opportunites in Antibody Drug Conjugate Market 2018-2019
Figure 11: Market Life Cycle Analysis in Antibody Drug Conjugate Market
Figure 12: GlobalBy PhaseAntibody Drug Conjugate Market Revenue, 2019-2024 ($)
Figure 13: GlobalBy Availability Antibody Drug Conjugate Market Revenue, 2019-2024 ($)
Figure 14: Global Antibody Drug Conjugate Market - By Geography
Figure 15: Global Antibody Drug Conjugate Market Value & Volume, By Geography, 2019-2024 ($) 
Figure 16: Global Antibody Drug Conjugate Market CAGR, By Geography, 2019-2024 (%)
Figure 17: North America Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 18: US Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 19: US GDP and Population, 2018-2019 ($)
Figure 20: US GDP – Composition of 2018, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2018-2019 ($)
Figure 22: Canada Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 23: Canada GDP and Population, 2018-2019 ($)
Figure 24: Canada GDP – Composition of 2018, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 26: Mexico Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 27: Mexico GDP and Population, 2018-2019 ($)
Figure 28: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 30: South America Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 31: Brazil Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 32: Brazil GDP and Population, 2018-2019 ($)
Figure 33: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 35: Venezuela Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 36: Venezuela GDP and Population, 2018-2019 ($)
Figure 37: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 39: Argentina Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 40: Argentina GDP and Population, 2018-2019 ($)
Figure 41: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 43: Ecuador Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 44: Ecuador GDP and Population, 2018-2019 ($)
Figure 45: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 47: Peru Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 48: Peru GDP and Population, 2018-2019 ($)
Figure 49: Peru GDP – Composition of 2018, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 51: Colombia Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 52: Colombia GDP and Population, 2018-2019 ($)
Figure 53: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 55: Costa Rica Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 56: Costa Rica GDP and Population, 2018-2019 ($)
Figure 57: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 59: Europe Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 60: U.K Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 61: U.K GDP and Population, 2018-2019 ($)
Figure 62: U.K GDP – Composition of 2018, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 64: Germany Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 65: Germany GDP and Population, 2018-2019 ($)
Figure 66: Germany GDP – Composition of 2018, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 68: Italy Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 69: Italy GDP and Population, 2018-2019 ($)
Figure 70: Italy GDP – Composition of 2018, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 72: France Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 73: France GDP and Population, 2018-2019 ($)
Figure 74: France GDP – Composition of 2018, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2018-2019 ($)
Figure 76: Netherlands Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 77: Netherlands GDP and Population, 2018-2019 ($)
Figure 78: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 80: Belgium Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 81: Belgium GDP and Population, 2018-2019 ($)
Figure 82: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 84: Spain Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 85: Spain GDP and Population, 2018-2019 ($)
Figure 86: Spain GDP – Composition of 2018, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 88: Denmark Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 89: Denmark GDP and Population, 2018-2019 ($)
Figure 90: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 92: APAC Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 93: China Antibody Drug Conjugate Market Value & Volume, 2019-2024
Figure 94: China GDP and Population, 2018-2019 ($)
Figure 95: China GDP – Composition of 2018, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2018-2019 ($)Antibody Drug Conjugate Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 97: Australia Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 98: Australia GDP and Population, 2018-2019 ($)
Figure 99: Australia GDP – Composition of 2018, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 101: South Korea Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 102: South Korea GDP and Population, 2018-2019 ($)
Figure 103: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 105: India Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 106: India GDP and Population, 2018-2019 ($)
Figure 107: India GDP – Composition of 2018, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2018-2019 ($)
Figure 109: Taiwan Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 110: Taiwan GDP and Population, 2018-2019 ($)
Figure 111: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 113: Malaysia Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 114: Malaysia GDP and Population, 2018-2019 ($)
Figure 115: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 117: Hong Kong Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 118: Hong Kong GDP and Population, 2018-2019 ($)
Figure 119: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 121: Middle East & Africa Antibody Drug Conjugate Market Middle East & Africa 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 122: Russia Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 123: Russia GDP and Population, 2018-2019 ($)
Figure 124: Russia GDP – Composition of 2018, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 126: Israel Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 127: Israel GDP and Population, 2018-2019 ($)
Figure 128: Israel GDP – Composition of 2018, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 130: Entropy Share, By Strategies, 2018-2019* (%)Antibody Drug Conjugate Market 
Figure 131: Developments, 2018-2019*Antibody Drug Conjugate Market 
Figure 132: Company 1 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 133: Company 1 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 134: Company 1 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 135: Company 2 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 136: Company 2 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 137: Company 2 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 138: Company 3Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 139: Company 3Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 140: Company 3Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 141: Company 4 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 142: Company 4 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 143: Company 4 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 144: Company 5 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 145: Company 5 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 146: Company 5 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 147: Company 6 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 148: Company 6 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 149: Company 6 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 150: Company 7 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 151: Company 7 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 152: Company 7 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 153: Company 8 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 154: Company 8 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 155: Company 8 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 156: Company 9 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 157: Company 9 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 158: Company 9 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 159: Company 10 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 160: Company 10 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 161: Company 10 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 162: Company 11 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 163: Company 11 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 164: Company 11 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 165: Company 12 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 166: Company 12 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 167: Company 12 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 168: Company 13Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 169: Company 13Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 170: Company 13Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 171: Company 14 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 172: Company 14 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 173: Company 14 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 174: Company 15 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 175: Company 15 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 176: Company 15 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)